Halozyme Therapeutics (HALO) Non-Current Deffered Revenue (2010 - 2023)

Halozyme Therapeutics (HALO) has 14 years of Non-Current Deffered Revenue data on file, last reported at $2.3 million in Q3 2023.

• Non-Current Deffered Revenue for Q3 2023 came in at $2.3 million, down 20.47% year-over-year; the trailing twelve-month figure through Sep 2023 was $2.3 million (down 20.47% YoY), and the FY2022 annual result was $2.3 million, down 10.95% from the prior year.
• Non-Current Deffered Revenue steadied at $2.3 million in Q3 2023 per HALO's latest filing, from $2.3 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $4.0 million in Q4 2020 and troughed at $641000.0 in Q3 2020.
• A 5-year average of $2.5 million and a median of $2.4 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2019 and 2021: Non-Current Deffered Revenue sank 75.1% in 2019, then jumped 294.7% in 2021.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $1.2 million in 2019, then soared by 222.85% to $4.0 million in 2020, then slumped by 37.16% to $2.5 million in 2021, then declined by 10.95% to $2.3 million in 2022, then changed by 0.0% to $2.3 million in 2023.
• Business Quant data shows HALO's Non-Current Deffered Revenue at $2.3 million in Q3 2023, $2.3 million in Q2 2023, and $2.3 million in Q1 2023.